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The effects of the antiaggregant substance ticlopidine and of the anticoagulant acenocoumarol on patency
rates oj aorto-coronary bypass grafts were compared in a prospective randomized trial. Ticlopidine, 250 mg
b.i.d. was administered orally from the first postoperative day till angiography, while anticoagulation with
acenocoumarol was initiated on the second to third postoperative day. Side-effects of ticlopidine were rare
and patient management with the standard dosage of this drug was easier than oral anticoagulation. From an
initial group of 166 randomized patients 149 completed the trial by coronary angiography three months post-
operatively. The 78 patients in the ticlopidine group showed a compliance of 85%. The average prothrombin
lime in the 71 patients receiving acenocoumarol was 26-9%. Detailed statistical analysis of the two study
groups revealed no reason to doubt the correctness of randomization.
Coronary angiography showed an average patency rate per patient of 84% with ticlopidine and of 82%
with acenocoumarol. This and various other measures of graft occlusion did not reveal any substantial differ-
ence in graft patency of patients receiving ticlopidine or acenocoumarol. It is concluded that ticlopidine may
well be used instead of anticoagulants for prevention of postoperative occlusion of aorto-coronary bypass
grafts.
Introduction platelet aggregation and prolonging bleeding time;
Long standing patency of aorto-coronary a P o t e n t antithrombotic activity has also been
bypass grafts is essential for good subjective and s h o w n i n a n i m a l models"8 ' . In mongrel dogs
objective results of surgical myocardial pretreatment with ticlopidine reduced adhesion
revascularization"21. About 10% of bypass grafts a n d aggregation of platelets on arterial dacron
become occluded within days of insertion and g r a f t s a n d significantly increased their patency rate
16-26% during the first postoperative year"-6 1 . UP t 0 6 w e e k s a f t e r implantation"91. In a
Thrombosis plays an important role in early graft randomized blinded clinical trial reported pre-
occlusion. while later obstruction is caused mainly viously from this institution, ticlopidine or placebo
by intimal proliferation and atherosclerosis13"5). w e r e s t a r t e d 3 d a y s b e f o r e b y P a s s surgery and were
For prevention of thrombosis, oral anticoagulants continued until angiography 3 months post-
and platelet active drugs, namely aspirin, alone or operatively; in addition all patients postoperatively
in combination with dipyridamole as well as received acenocoumarol as an oral antico-
sulfinpyrazone have been tested in animal exper- agulant1201. When very severe bleeding occurred in
iments [781and in clinical trials169"171 . a patient, this study had to be discontinued
Ticlopidine is a platelet inhibiting drug reducing prematurely. It was found that ticlopidine signifi-
cantly enhanced peri- and postoperative blood loss
Received for publication on 16 November 1984 and led to a 6-fold increase of reoperation for
Address for reprin,,-Hot. M. E. Roth.in. Department of Medicine. b l e e d i n g ' U Was Concluded, that preoperative
University Hospital. CH — 8091 Zurich. Switzerland administration of ticlopidine IS not justified,
0195 668X 85 020168 + 08 S02.00 0 ©1985 The European Society of Cardiology
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Table I Criteria for exclusion of patients from the study
1 Female sex
2 Previous bypass surgery
3 Additional surgical procedures such as left ventricular
aneurysmectomy or valve replacement
4 Emergency operations
5 Diabetes requiring insulin or oral hypoglycaemics
6 Haematologic disorders
7 Liver or kidney disorder
8 Need for drugs influencing platelet function (acetyl-
salicylic acid, sulfinpyrazone, dipyridamole, non steroid-
antiinflammatory agents, clofibrate)
9 Patients, who did not give informed consent
although this study had revealed a significant
reduction of perioperative infarction in patients
receiving preoperative ticlopidine'211. After 3
months, however, angiography did not show a
significant increase in graft patency in patients
treated pre- and postoperatively with ticlopidine.
The reported significant reduction of graft oc-
clusion by postoperative oral anticoagulation"01
raises the question, whether anticoagulants,
administered after surgery to all patients in our
study, had concealed a positive effect of ticlopidine
on graft occlusion. The present study was there-
fore designed to compare the effect of post-
operative treatment with ticlopidine with oral
anticoagulation by acenocoumarol with respect to
thrombotic occlusion of aorto-coronary bypass
grafts.
Patients and methods
PATIENT RANDOMIZATION
From February 1980 to August 1981, 407
patients had an aorto-coronary bypass operation
at the University Hospital Zurich. Unless patients
fulfilled any of the exclusion criteria listed in Table
1, they were asked to participate in the study. A
total of 166 patients consented and entered the
trial. For randomization, 83 patients each were
assigned to either ticlopidine or acenocoumarol by
opening a consecutively numbered sealed envelope
indicating the type of treatment. The envelopes
were previously prepared by a statistician from the
company providing ticlopidine according to a table
of random numbers. All patients submitted to
angiography 3 months postoperatively remained in
their original treatment group for analysis of
results, whether they adhered to their recom-
mended treatment or not.
MEDICATION AND MONITORING OF PATIENT
COMPLIANCE
Ticlopidine, 250 mg b.i.d. was administered
orally starting the first postoperative day until
angiography was performed 3 months post-
operatively. Each patient on ticlopidine treatment
received a bottle with 200 tablets at hospital dis-
charge, which was collected at the end of the study
(postoperative coronary angiography) for a tablet
count. Furthermore, platelet aggregation with col-
lagen was tested preoperatively, before hospital
discharge, 6 weeks after surgery and 3 months
postoperatively to monitor compliance'221.
Acenocoumarol was started after removal of
the drainage tubes on the second or third post-
operative day. Dosage was adjusted aiming at
a prothrombin time of 20-25%. The test was
performed using a substrate prepared from human
brain tissue. The prothrombin time determined
6 weeks postoperatively was used as a quality
control of oral anticoagulation.
ANGIOGRAPHY
Three months after surgery, native vessels and
bypass grafts were visualized by selective injections
in orthogonal views. At the same time, ventricular
cineangiography was performed in right and left
anterior oblique projections; pressures were
recorded before and after ventriculography. No
serious complications occurred during post-
operative angiographic studies. Angiograms were
analysed without knowledge of the patient's group
assignment by at least two observers. In case of
vein grafts with two or more distal anastomoses,
each segment was counted as one 'aorto-coronary
bypass', implantation of the internal mammary
artery into a coronary artery was also counted as
one 'aorto-coronary bypass'. Patency was classi-
fied as occluded (grade 4), obstructed by more than
75% (grade 3), by 50-75% (grade 2) not severely
stenosed including mild stenosis of less than 50%
(grade 1).
An aorto-coronary bypass was called 'patent', if
it was free of any grade 4 obstruction, and
'obstruction free', if no or only grade 2 stenosis
was present.
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For statistical analysis of the patency rate in two
treatment groups, individual bypass segments
should not be used as observation units, because
different bypass segments in an individual patient
are not independent. Therefore we calculated for
each patient a patency rate (PCY) defined as the
ratio of patent segments to implanted segments.
Moreover a rate of'obstruction free' bypass grafts
(PCY2) was similarly calculated: 100 times the
number of patent segments presenting with less
than 75% stenosis divided by the number of
implanted segments.
STATISTICAL METHODS
The base line data for the two groups were
compared both by univariate methods (t test for
continuous variables and chi squared test for
categorical variables) and by a stepwise logistic
regression with the treatment group as the depen-
dent variable. The main comparison of the treat-
ments was obtained from ordinary stepwise
regression with the two target variables described
above (PCY and PCY2) appearing in turn as
dependent variables and base line characteristics as
well as the type of medication as the independent
variables. The medication variable assumed the
value 0 for anticoagulation, and the value 1 for
ticlopidine treatment. It was forced to enter the
equation in order to obtain a confidence interval
for its coefficient, which represents the treatment
effect.
To get adequate results for the statistical tests,
the patients had to be used as the observation units
rather than the individual segments, since the
patencies of the segments within the same patient
showed a statistically significant correlation.
The calculations were done using BMCP pro-
grams at the computer center of Zurich University.
Results
PATIENT ADHERENCE, SIDE-EFFECTS AND COMPLIANCE
Out of 166 patients recruited for the trial, 5
receiving ticlopidine and 12 receiving antico-
agulants, did not undergo angiography 3 months
postoperatively; this corresponds to a drop out
rate of 10%. Reasons for not performing control
angiography are listed in Table 2. Seventy-eight
patients in the ticlopidine-group and 71 patients in
the anticoagulant-group completed the study with
postoperative coronary angiography. In addition
to the complications possibly related to the type of
treatment in Table 2, one patient receiving antico-
Table 2 Causes of not performing control angiography (drop
out patients— D.O.) and side-effects requiring premature dis-
continuation of treatment in patients (C.S.), who completed
the study
Anticoagulation Ticlopidine
DO. C.S. DO. C.S.
Stroke
Haematuria
Intestinal haemorrhage
Myocardial infarction
Sudden death
Pulmonary embolism
Left heart failure
Nausea and anorexia
Refusal by patient or
private physician
— 2f
1 —
1* —
I
•Direct side-effects
tPossible indirect side-effect, because patients did not
receive anticoagulants
agulants experienced cerebral haemorrhage but
was submitted to control angiography in spite of
premature cessation of anticoagulants. In the
ticlopidine-group, 4 patients discontinued medi-
cation prematurely: 2 because of severe gastro-
intestinal symptoms and 2 because ticlopidine
was replaced by anticoagulants when the private
physician suspected pulmonary embolism.
Patient compliance in the ticlopidine-group was
84% according to the tablet count and 86% when
assessed by inhibited platelet aggregation. In
patients receiving anticoagulants, prothrombin
time determined 6 weeks postoperatively averaged
26-96+ 12-30 (SD)%.
COMPARISON OF THE TWO TREATMENT GROUPS
Some selected preoperative characteristics of the
two treatment groups are tabulated in Table 3.
Table 4 illustrates operative characteristics of the
two treatment groups. Comparison of base line
data by univariate methods did not show any sig-
nificant difference at the 5% level between the
treatment groups. Moreover in a logistic stepwise
regression run on 36 historical, clinical, angio-
graphic and operative variables recorded before
starting treatment, only 3 variables entered the
regression equation with a P value of less than 5%:
perioperative infarction and a bypass to an inter-
mediate branch of the left coronary artery were less
frequent in the ticlopidine-group, anastomosis
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Table 3 Preoperative characteristics of the two treatment
groups
Anticoagulation Ticlopidine
Age (years) 53-5+ 8-2 53-2+ 6-7
Duration of symptoms
(months) 40-2±43-6 39-3±42-8
Previous myocardial
infarction (%) 62 59
Average NYHA-class 2-6+ 0-7 2-4+ 0-6
Physical working capa-
city,
% of predicted 62-9 + 24-6 62-4 ±27-3
Smoking, average pack
years 22-3±21-3 20-2+17-2
Ejection fraction (%) 57-3+10-6 59-5± 8-9
LVEDP(mmHg) 13 8+ 6-7 13-6± 50
Coronary score* 7-8+ 2-6 7-4+ 2-7
Number of main bran-
ches with obstructions 2-3+ 0-8 2-4+ 0-7
*Dash H, Johnson RA, Dinsmore RE, Harthorne JW, Car-
diomyopathic syndrome due to coronary artery disease. Br
Heart J 1977; 39: 733-9.
of a bypass to a postero-lateral branch of the
right coronary artery was less common in the
anticoagulant-group
ANGIOGRAPHIC PATENCY RATE OF AORTO-CORONARY
BYPASS
Cineangiographic examination of patency of the
aorto-coronary bypass did not reveal any substan-
tial difference between the two treatment groups.
Thirty out of 78 patients with ticlopidine and 30
out of 71 patients with anticoagulants had at least
one occluded graft segment. Two patients out of 78
with ticlopidine and one patient out of 71 with
anticoagulants had all grafts occluded. The aver-
age patency rate per patient (PCY) and the rate of
'obstruction free' bypass per patient (PCY2) were
very similar in both patient groups when compared
in a histogram, as can be seen in Figs 1 and 2.
A regression characterizing patients before
medication including the location of the bypass
segments, the size of the anastomosed coronary-
artery, need for endarterectomy and type of bypass
graft as possible risk factors for obstruction was
performed for PCY and PCY2 (Table 5). Although
a large number of possibly influential variables was
examined, there was almost no influence of any of
these on bypass patency with the exception of
perioperative infarction and anastomosis to a third
postero-lateral branch of the circumflex artery.
The confidence intervals obtained for the true
treatment effect (see statistical methods) range
from - 7 % to +7% for PCY and from - 8 % to
+ 10% for PCY2. This means that the two treat-
ments had virtually identical effects on the patency
of the grafts.
Discussion
The presented findings indicate, that the
regimens of ticlopidine, an anti-platelet drug, and
acenocoumarol, an oral anticoagulant, had virtu-
ally identical effects on aorto-coronary bypass
graft patency studied 3 months after implantation.
The drop out rate of 10% in this trial compares
favourably with that reported in previous trials
testing platelet active drugs on patency of aorto-
coronary bypass grafts'6'10"161. The lack of sig-
nificant differences in univariate analysis of
patient characteristics of the two treatment groups
indicates proper randomization. Multivariate
analysis showed only 3 variables, namely two
uncommon localizations of graft anastomoses and
perioperative infarction to enter the equation with
a P value of less than 5%. Other risk factors
for bypass occlusion including size of the grafted
vessel, endarterectomy, use of Y-shaped grafts and
single, double or multiple sequential grafts were
not found to differ significantly in the two treat-
ment groups. It was therefore concluded that there
are no reasons to doubt the correctness of the
randomization.
Patient compliance was satisfactory with about
15% of patients not taking ticlopidine regularly
because of side-effects or insufficient cooperation.
Prothrombin time determined 6 weeks post-
operatively for testing the quality of anticoagu-
lation with acenocoumarol averaged 26% and was
somewhat higher than expected. Side-effects of
ticlopidine were rare, only 3 patients discontinued
the drug for nausea and anorexia. In the aceno-
coumarol group, there was cerebral haemorrhage,
gastrointestinal haemorrhage and haematuria in
one patient each. In no patient did permanent
sequelae of the above mentioned side-effects occur.
An indirect effect of ticlopidine treatment as
compared with oral anticoagulants may be seen in
the occurrence of pulmonary embolism in two
patients and suspicion of this complication in
another two. Pulmonary embolism is recorded
exceptionally in our experience with routine
anticoagulation after aorto-coronary bypass
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Table 4 Operative characteristics of the two treatment groups
Anticoagulation Ticlopidine
(JV = 78)
Aortic clamping time (min)
Grafts per patient
Number of segments per patient
Perioperative myocardial infarc-
tion
Rethoractomy for haemorrhage
1
2
3
4
5
6
50-9+ 19 2
3-2+ 11
6
12
23
24
4
2
7
3
51-2 + 19-6
3 1 + 10
3
21
24
24.
4
0
2
3
a.
"6
6
40 -
30 -
20
10
Tidopidine
(A/ = 78)
50 100% PCY 0
Anticoagulants
(/V= 71)
- I ll
50 100% PCY
Figure
PCY =
PCY PCY
Rate of patent bypass
/ Histogram of individual patency rates (PCY) in patients with ticlopidine (average
84-2%) or acenocoumarol (average PCY = 81-6%).
operation. On the other hand this complication
was the most common cause of postoperative
morbidity in the Stanford series'23'before heparin
was instituted routinely after the immediate
operative period. In previously reported clinical
studies on the prevention of bypass graft occlu-
sion, pulmonary embolism had been repeatedly
observed1911121. The risk of pulmonary embolism
is an additional indication for prophylactic anti-
thrombotic measures during the early postoper-
ative period. In the previously reported studies
on the effect of anticoagulants or platelet active
drugs on bypass patency, this problem has not
been discussed, however"9-12-23'.
After administration of either drug from the first
to third postoperative day until angiography three
months postoperatively, both treatment groups
showed a very similar patency rate. This was the
case for the total number of implanted bypass seg-
ments and for all segments anastomosed to the
same individual coronary vessel. Since the patency
of grafts from the same patient are not statistically
independent variables, the individual graft seg-
ments were not used as observation units when
performing statistical tests. The average patency
rate per patient and the average rate of obstruction
free bypass per patient were therefore preferred
for statistical analysis. None of these variables
revealed a significant difference in graft patency of
patients receiving ticlopidine or acenocoumarol
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Ticiopidme
t/V= 78)
Anticooguiants
(/V = 71)
v
 40
c
| 30
5
c 20
oo
•s IC
o
z
0
a
50 100% PCY2 0 50 100% PCY2
PCY, PCY2
Rate of 'obstruction-free' bypass
Figure 2 Histogram of individual 'obstruction free" rates (PCY2), indicating less than 75%
obstruction, in patients treated with ticlopidine (average PCY2 = 750%) or acenocoumarol (average
PCY2 = 74-5%).
Table 5 Variables entering a regression characterizing patients before
entering into study
Independent variable
Perioperative infarction
Third posterolateral branch
anastomosis
Medication*
Constant
R2
Confidence interval
PCY
Coeff
-0-303
-0-370
- 0 0 0 0 3
0-687
016
F
14-8
5-3
00
- 0 0 7 4 - + 0-075
PCY2
Coeff F
— —
0014 009
0-745
00
- 0 0 7 8 - + 0-105
•Medication was forced of enter the regression.
(Figs 1 and 2). There were also no significant dif-
ference in the patient number with all grafts patent
or with all grafts occluded in the two treatment
groups. The calculated 95% confidence interval of
graft patency indicates that the difference between
the two types of treatment may vary between a
reduction of graft occlusion by 7% and an
enhancement of graft occlusion by 7%. The cor-
responding values for rate of obstruction free
grafts varied from a reduction of graft obstruction
by 8% to an enhancement of graft obstruction by
10%. Therefore for practical purposes it can be
said from these observations, that there is no dif-
ference with regard to patency rate between the
two types of treatment.
Progression of stenotic lesions in native coron-
ary arteries of the two treatment groups has been
studied and reported separately'251. Progression of
obstruction was significantly more frequent in
vessels with a bypass, particularly in lesions
located proximal to a bypass anastomosis. Stenosis
at the site of anastomosis itself was more common,
if the bypass graft was occluded. Regarding the
postoperative antithrombotic regimen no sub-
stantial difference in progression of stenotic
lesions in native vessels was observed between
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patients receiving ticlopidine and those receiving
acenocoumarol.
A drawback of the present clinical trial is the
lack of a placebo group. After the report of a sig-
nificant benefit of anticoagulants"01 regarding
patency of bypass grafts, the inclusion of a control
group receiving no antithrombotic treatment was
not acceptable to all participants of this trial.
Direct proof that ticlopidine has beneficial effect
on bypass graft patency can therefore not be
derived from our data. Chevigne et a/.12*1 have
studied ticlopidine in a blinded trial after bypass
surgery and very recently reported it to be an effec-
tive means to protect bypass patency in a subgroup
of their randomized patients, who showed com-
pliance to the treatment and who were restudied in
time according to their protocol. Indirect evidence
of an inhibitory effect of ticlopidine on bypass
occlusion can also be derived from the present
observations, since this drug was found to be as
active as oral anticoagulants, which showed a
significant beneficial effect on bypass patency in a
previous trial'81. A beneficial effect of oral antico-
agulation had previously been postulated by
McEnany et a/.1121, while Pantely et al.l9] could not
find a significant difference in their very small
series.
Preoperative administration of a platelet active
agent would be most desirable, because platelet
deposition occurs within seconds after implan-
tation of a graft into the blood stream"91 and
can be influenced by preoperative administration
of ticlopidine in animal experiments"91. In our
previously reported trial1201, preoperative adminis-
tration of ticlopidine significantly enhanced post-
operative blood loss and the rate of reexplorations
for bleeding. Although in other clinical studies no
statistically significant difference in bleeding had
been reported in cardiac surgery'26-271 or after pro-
statectomy'281, we concluded that preoperative
routine administration of ticlopidine is not justi-
fied. In the limited experience with preoperative
administration of ticlopidine there was no benefic-
ial effect on patency rate'201; however, the incidence
of perioperative infarctions was significantly redu-
ced'21'. In this regard it is of interest, that aspirin,
which prolongs bleeding time like ticlopidine, has
been reported to increase the risk of postoperative
bleeding '29'. This drug was withheld before
surgery in clinical trials on prevention of bypass
graft occlusion'9""1416 ' , even in the study of
Chesebro'13', where the importance of preopera-
tive start of medication was emphasized.
Conclusions
Interference with the pathways of thrombus
formation in order to prevent thrombotic
occlusion of aorto-coronary bypass is a two-edged
venture. The treatment should be started before
graft implantation for optimal effect, but the
risk of operative and postoperative bleeding is
against this. Moreover, pericardial effusion
occurs frequently within the first two weeks after
cardiac surgery and in association with antico-
agulation cardiac tamponade may develop'30-3".
Finally the protective effect regarding venous
thrombosis and pulmonary embolism should be
considered. Aspirin, alone or in association to
dipyridamole'611"1316-171, sulfinpyrazone"41 and
oral anticoagulants'101 have all shown favourable
results in some trials, but no benefit in others'9'15l.
Ticlopidine has been shown to be effective in one
study'251. In combination with oral anticoagulation
it had no additional effect as compared with anti-
coagulation alone regarding patency rate.'20'. The
present data indicate, that ticlopidine is as effective
as oral anticoagulants if administered post-
operatively. Side-effects were less common with
ticlopidine than with anticoagulants and patient
management was easier with a standard dosage of
ticlopidine as compared with the individual adjust-
ment of acenocoumarol to prothrombin time. If
there is no increased risk for venous thrombosis
and pulmonary embolism, ticlopidine may well be
used instead of anticoagulants for the prevention
of aorto-coronary bypass occlusion.
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